Pancreatic Cancer Research

ResearcherUniversity of FoggiaActive in the last 2 years

Valerio Pazienza

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3492-1153; OpenAlex author ID A5085445167. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
60
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: 3 papers · 2017: 3 papers · 2018: 1 paper · 2019: 4 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 30

  1. The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response. Co-author DOI 10.3390/biomedicines14061407↗
  2. Comparative Analysis of Fecal Microbiota in Healthy Controls and Pancreatic Cancer Patients: A Focus on Tumor Localization Differences in Pancreatic Head and B… Last author DOI 10.1002/cam4.71450↗
  3. Microbiota as a state-of-the-art approach in precision medicine for pancreatic cancer management: A comprehensive systematic review. Co-author DOI 10.1016/j.isci.2025.112314↗
  4. Integrated periodontal pathogens and circulating miRNAs: a novel non-invasive panel of biomarkers for pancreatic cancer. First author DOI 10.3389/fcimb.2025.1678114↗
  5. A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic p… Last author DOI 10.1080/19490976.2024.2375483↗
  6. Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS G12D mutated pancreatic cancer in vivo model. Last author DOI 10.1038/s41420-023-01397-y↗
  7. Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models. Last author DOI 10.1016/j.biopha.2022.113163↗
  8. Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspe… Last author DOI 10.1016/j.semcancer.2021.11.007↗
  9. Tuning gut microbiota through a probiotic blend in gemcitabine-treated pancreatic cancer xenografted mice. Last author DOI 10.1002/ctm2.580↗
  10. Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels. Last author DOI 10.3390/biom11050639↗
  11. Inhibition of pyruvate dehydrogenase kinase influence microbiota and metabolomic profile in pancreatic cancer xenograft mice. Last author DOI 10.1186/s13104-020-05384-9↗
  12. High Levels of Prebiotic Resistant Starch in Diet Modulate a Specific Pattern of miRNAs Expression Profile Associated to a Better Overall Survival in Pancreati… Last author DOI 10.3390/biom11010026↗
  13. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  14. Body site-dependent variations of microbiota in pancreatic cancer pathophysiology. First author DOI 10.1080/10408363.2019.1615407↗
  15. Dichloroacetate Affects Mitochondrial Function and Stemness-Associated Properties in Pancreatic Cancer Cell Lines. Co-author DOI 10.3390/cells8050478↗
  16. High Levels of Prebiotic Resistant Starch in Diet Modulate Gene Expression and Metabolomic Profile in Pancreatic Cancer Xenograft Mice. Last author DOI 10.3390/nu11040709↗
  17. Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Last author DOI 10.1007/s00280-018-3549-0↗
  18. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  19. Rewiring carbohydrate catabolism differentially affects survival of pancreatic cancer cell lines with diverse metabolic profiles. Co-author DOI 10.18632/oncotarget.17172↗
  20. Engineered Resistant-Starch (ERS) Diet Shapes Colon Microbiota Profile in Parallel with the Retardation of Tumor Growth in In Vitro and In Vivo Pancreatic Canc… Last author DOI 10.3390/nu9040331↗
  21. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  22. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Last author DOI 10.18632/oncotarget.6808↗
  23. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. Last author DOI 10.18632/oncotarget.7108↗
  24. Functional Impact of Autophagy-Related Genes on the Homeostasis and Dynamics of Pancreatic Cancer Cell Lines. Last author DOI 10.1109/tcbb.2014.2371824↗
  25. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Last author DOI 10.18632/oncotarget.4186↗
  26. SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation. First author DOI 10.3109/07420528.2014.1003351↗
  27. Targeting human equilibrative nucleoside analog transporter (hENT1) expression through modified low glycemic index diet in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2014.04.009↗
  28. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clini… Last author DOI 10.1186/s12967-014-0248-4↗
  29. Correlations among PPARγ, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer. Co-author DOI 10.1155/2012/461784↗
  30. Time-Qualified Patterns of Variation of PPARγ, DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines. Co-author DOI 10.1155/2012/890875↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Concetta Panebianco · 16 shared papers, 2015–2026 · strength 2.27
  2. Tiziana Pia Latiano · 9 shared papers, 2020–2026 · strength 1.58
  3. Annacandida Villani · 9 shared papers, 2019–2025 · strength 1.41
  4. Francesco Perri · 8 shared papers, 2020–2025 · strength 1.25
  5. Evaristo Maiello · 4 shared papers, 2014–2025 · strength 0.61
  6. Zeinab Hesami · 2 shared papers, 2025 · strength 0.51
  7. Amir Sadeghi · 2 shared papers, 2025 · strength 0.51
  8. Hamidreza Houri · 2 shared papers, 2025 · strength 0.51
  9. Nadia Trivieri · 3 shared papers, 2020–2025 · strength 0.50
  10. Andrea Fontana · 7 shared papers, 2012–2024 · strength 0.47
  11. Kaarel Adamberg · 3 shared papers, 2017–2020 · strength 0.33
  12. Marco Donatello Delcuratolo · 1 shared paper, 2026 · strength 0.33
  13. Angelo Andriulli · 7 shared papers, 2012–2018 · strength 0.33
  14. Francesca Tavano · 7 shared papers, 2012–2017 · strength 0.29
  15. Samira Alipour · 1 shared paper, 2025 · strength 0.27
  16. Babak Khorsand · 1 shared paper, 2025 · strength 0.27
  17. Tommaso Mazza · 4 shared papers, 2015–2016 · strength 0.22
  18. Carmela Mazzoccoli · 2 shared papers, 2017–2019 · strength 0.16
  19. Cláudia Piccoli · 2 shared papers, 2017–2019 · strength 0.16
  20. Tiziana Tataranni · 2 shared papers, 2017–2019 · strength 0.16
  21. Fabio F. di Mola · 4 shared papers, 2012–2015 · strength 0.14
  22. Pierluigi Di Sebastiano · 4 shared papers, 2012–2015 · strength 0.14
  23. Gianluigi Mazzoccoli · 3 shared papers, 2012–2015 · strength 0.12
  24. Iole Maria Di Gangi · 2 shared papers, 2016 · strength 0.11
  25. Alessandro Del Nobile Matteo · 1 shared paper, 2014 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.